Analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the stock.
NovaBay Pharmaceuticals Stock Down 2.7 %
Shares of NBY stock opened at $0.71 on Monday. The stock has a 50-day simple moving average of $0.66 and a 200 day simple moving average of $2.31. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $17.40. The stock has a market capitalization of $768,220.00, a P/E ratio of -0.01 and a beta of 0.73.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. On average, sell-side analysts anticipate that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current year.
Institutional Investors Weigh In On NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is the Hang Seng index?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.